eyesON | Phase II Vanguards
Phase II Vanguards data visualization tool provides oversight of groundbreaking investigational new drugs and under-the-radar institutions developing them.
Phase II Vanguards data visualization tool provides oversight of groundbreaking investigational new drugs and under-the-radar institutions developing them.
The latest Community Learning Session with our CEO, Artem Andrianov took us into the world of AI-driven automation, focusing on how AI Automation & Productivity and other AI tools can streamline workflows, reduce manual effort, and enhance productivity. Automating Repetitive Tasks AI can handle [...]
Discover how the finalized ICH E6(R3) guideline elevates site and sponsor collaboration, emphasizing robust training, resource allocation, and digitally empowered data governance. This concise article outlines critical updates, from risk-based monitoring to formalized documentation, ensuring your clinical trial operations align with leading edge GCP requirements and maintain the highest standards of patient safety and data integrity.
Communication Skills: Speaking for Effect Do you ever feel like your words don’t land the way you intend? Maybe you’ve shared an idea, but the reaction wasn’t what you expected. Communication isn’t just about speaking it’s about making sure your message is understood [...]
Do You Set Goals? How Do You Keep Them in Sight? Some people write their goals in a notebook, others use digital trackers, post-it notes, or vision boards. But what really works to stay on track? That was the focus of our latest [...]
Cyntegrity’s MyRBQM Portal is the first clinical trial data science software to achieve Microsoft Healthcare AI Certification following a rigorous independent audit. This recognition underscores our commitment to ethical, reliable AI solutions and patient safety. Learn more about this milestone and our AI-driven advancements in clinical trials: Read the full article.
Join Cyntegrity at DIA 2025, June 15–19 in Washington, DC! Don’t miss our CEO, Artem Andrianov, sharing insights on advancing clinical research.
Join Cyntegrity at SCOPE 2025, Feb 3–6, Booth #408, to explore RBQM solutions, connect with our experts, and transform your clinical trial operations.
The ICH E6(R3) guideline was formally adopted on January 6, 2025, introducing reinforced principles for clinical trial conduct. This final version builds on its draft with clarified expectations and some notable revisions. Let’s explore the highlights and the implications for stakeholders.
With ICH E6(R3) reinforcing proactive quality management, relying on EDC systems with hundreds of edit checks is impractical. The MyRBQM Portal bridges the gap with predictive analytics, historical data views, and real-time risk drill-downs, enhancing oversight and reducing complexity. Learn how EDC and RBQM work together for more insightful, compliant trial management.
The ICH E6(R3) guideline redefines expectations for clinical trial sites, emphasizing proactive planning, data accuracy, and risk monitoring to enhance participant safety and trial efficiency. Download our presentation for practical insights and strategies to ensure compliance and strengthen collaboration.